NEW YORK (GenomeWeb) – GenomOncology announced today that pathology services company Pathline Emerge has begun using its GO Clinical Workbench for analysis and reporting of next-generation sequencing tests.
Financial terms of the deal were not disclosed.
Pathline partnered with GenomOncology in order to find ways to streamline its workflows and deliver detailed reports to clinicians, the company said in a statement. The GO Clinical Workbench enables labs to configure workflows for molecular tests based on NGS, FISH, karyotyping, RT-PCR, IHC, and others. Specifically, labs can perform quality control analysis, evaluate all variants, and send clinical reports.
"One key area of value creation is being able to provide oncologists with reports that provide decision support over integrated data sets," said GenomOncology President and CEO Manuel Glynias in a statement. "Therapy decisions can change depending on co-occurring genomic aberrations and it's important for the oncologist to understand these potential changes — for example, combining gene fusion data with karyotype results, SNVs, and indels to provide an integrated interpretative report that proposes therapeutic options and suggests appropriate clinical trials."
In November, GenomOncology announced a deal to comarket ArcherDx's next-generation sequencing assays alongside the GO Clinical Workbench, and to support interpretation of several ArcherDx assays, including the ALK, RET, ROS1, Solid Tumor, and Comprehensive Thyroid and Lung panels.